Determining the effect of dairy product enriched with glucomannan and inulin on hormonal indicators of appetite and quality of life in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240925063166N1

Enrollment

Registered

2025-05-17

Start date

2025-05-31

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. E11.9 – Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: "The intervention group will receive 150 ml of low-fat yogurt enriched with glucomannan and inulin once daily, along with standard diabetic dietary recommendations.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Body Mass Index (BMI) between 25 kg/m² and less than 35 kg/m² No use of medications that affect appetite, body weight, or have anti-inflammatory properties No participation in any weight loss programs during the past 6 months (i.e., less than 10% weight reduction in the past 6 months) No significant change in physical activity during the past 4 weeks No use of antioxidants, multivitamins, or any type of dietary supplements in the past 3 months

Exclusion criteria

Exclusion criteria: Pregnancy or lactation History of gastrointestinal or bariatric surgery Liver dysfunction History of alcohol or other substance abuse History of endocrine disorders (especially hypothyroidism)

Design outcomes

Primary

Measure	Time frame
"Leptin and adiponectin hormone levels – measuring changes in the quality of life of patients with type 2 diabetes using validated scales such as the Diabetes Quality of Life Scale.". Timepoint: "At baseline and at the end of the study (2 months later)". Method of measurement: "Serum levels of leptin and adiponectin will be measured using ELISA kits at baseline and two months after the intervention. Quality of life will be assessed using the standardized Diabetes Quality of Life Questionnaire at the beginning and end of the study.".	—

Measure

Time frame

"Leptin and adiponectin hormone levels – measuring changes in the quality of life of patients with type 2 diabetes using validated scales such as the Diabetes Quality of Life Scale.". Timepoint: "At baseline and at the end of the study (2 months later)". Method of measurement: "Serum levels of leptin and adiponectin will be measured using ELISA kits at baseline and two months after the intervention. Quality of life will be assessed using the standardized Diabetes Quality of Life Questionnaire at the beginning and end of the study.".

—

Secondary

Measure	Time frame
Scores of depression, anxiety, and stress based on the DASS-21 questionnaire. Timepoint: "At baseline and at the end of the study (2 months later)". Method of measurement: The 21-item Depression, Anxiety, and Stress Questionnaire will be used to assess the psychological status of participants at baseline and at the end of the 2-month intervention. This instrument consists of three separate subscales: depression, anxiety, and stress.	—

Measure

Time frame

Scores of depression, anxiety, and stress based on the DASS-21 questionnaire. Timepoint: "At baseline and at the end of the study (2 months later)". Method of measurement: The 21-item Depression, Anxiety, and Stress Questionnaire will be used to assess the psychological status of participants at baseline and at the end of the 2-month intervention. This instrument consists of three separate subscales: depression, anxiety, and stress.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiavash Baba Jafari Esfand Abad

Shiraz University of Medical Sciences

jafaris@sums.ac.ir+98 71 3725 1005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026